BUZZ - ArriVent shares fall as its lung cancer drug fails to meet goals in late-stage clinical trial
路透社2026/10/06 12:49On October 6, shares of drug developer ArriVent BioPharma (AVBP.O) dropped 62.7% to $10.62 in pre-market trading. The company stated that its experimental drug firmonertinib failed to significantly delay disease progression or death in a late-stage clinical trial involving 398 previously untreated patients with advanced lung cancer associated with a rare genetic mutation. In the higher-dose group, the median time patients lived without cancer progression was 11 months, compared to 9.5 months in the chemotherapy group; additionally, 60% of patients saw tumor shrinkage, versus 33% in the chemotherapy group. In the high-dose group, 52% of patients experienced serious side effects, compared to 55% in the chemotherapy group; no new safety issues were reported. ArriVent is reviewing the full results to determine the next steps for the drug's development. As of the previous trading day's close, AVBP had risen 41.5% so far this year. (For ease of use by non-English speakers, Reuters offers its reports translated automatically into several languages. Automated translations may be inaccurate or may not adequately convey the intended meaning. Reuters does not guarantee the accuracy of these translations and provides them solely for reader convenience. Reuters accepts no liability for any damages or losses incurred from the use of the automated translation service.)
October 6 - ** Drug developer ArriVent BioPharma (AVBP.O) shares fell 62.7% to $10.62 in pre-market trading
** The company stated that its experimental drug firmonertinib (link) failed to significantly delay disease progression or death in a late-stage clinical trial involving 398 previously untreated patients with advanced lung cancer associated with a rare genetic mutation
** In the higher-dose group, the median time without cancer progression was 11 months, compared to 9.5 months in the chemotherapy group; meanwhile, 60% of patients saw tumor shrinkage, versus 33% in the chemotherapy group
** In the high-dose group, 52% of patients experienced serious side effects, compared to 55% in the chemotherapy group; no new safety issues were reported
** ArriVent is reviewing the full results to decide the next steps in the drug's development
** As of the previous trading day’s close, AVBP was up 41.5% year to date
(To assist non-English native speakers, Reuters provides automated translations of its reports in several languages. Due to potential inaccuracies or missing contextual nuance in automated translations, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters accepts no liability for any damages or losses arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
Australian Dollar: Neutral outlook inside tight range against US Dollar – UOB
Power Root buys back shares for MYR 147,891.13
Power Root bought back 134,300 ordinary shares on Oct. 7, 2026, paying MYR 147,891.13. Purchases were priced between MYR 1.08 and MYR 1.12; all shares were retained as treasury stock. Treasury shares rose to 16,051,800, representing 3.78% of issued shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Power Root Bhd published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3712895) on October 07, 2026, and is solely responsible for the information contained therein.
EPF Board trims IOI Corp stake, disposes 800,000 shares; holding at 18.651%
Malaysia’s EPF cut its stake in IOI Corp via the disposal of 800,000 ordinary shares on Oct. 2, 2026. EPF’s direct holding stood at 1,172,249,528 shares, equal to 18.65% of issued shares, following the transaction. The disclosure was dated Oct. 5, 2026, with the company receiving the notice on Oct. 7, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IOI Corporation Berhad published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3712867) on October 07, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
